The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Deacetylation of p53 modulates its effect on cell growth and apoptosis
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Self-citationA Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
The complexity of p53 modulation: emerging patterns from divergent signals
Giaccia, A. J., & Kastan, M. B. (1998) · Genes & Development · doi:10.1101/gad.12.19.2973 · Cited by 1,314
DNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204
Zhang, Y., Ng, H.-H., Erdjument-Bromage, H., Tempst, P., Bird, A., & Reinberg, D. (1999) · Genes & Development · doi:10.1101/gad.13.15.1924 · Cited by 1,103
Xue, Y., Wong, J., Moreno, G. T., Young, M. K., Côté, J., & Wang, W. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80299-3 · Cited by 985
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras
Pearson, M., Carbone, R., Sebastiani, C., Cioce, M., Fagioli, M., Saito, S., Higashimoto, Y., Appella, E., Minucci, S., Pandolfi, P. P., et al. (2000) · Nature · doi:10.1038/35018127 · Cited by 847
Zhang, Y., LeRoy, G., Seelig, H.-P., Lane, W. S., & Reinberg, D. (1998) · Cell · doi:10.1016/s0092-8674(00)81758-4 · Cited by 816
Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation
Wade, P. A., Gegonne, A., Jones, P. L., Ballestar, E., Aubry, F., & Wolffe, A. P. (1999) · Nature Genetics · doi:10.1038/12664 · Cited by 811
Cited by
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
“For example, the gene regulatory activity of transcription factors such as E2F1, p53, STAT1, STAT3 and NF-κB can be modulated through direct acetylation and deacetylation of the factors themselves, and all of these proteins are hyperacetylated in response to HDAC”
BackgroundhSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Self-citationErasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610
Self-citationAcetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
The Sir2 Family of Protein Deacetylases
Blander, G., & Guarente, L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073651 · Cited by 1,495
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
miR-34a repression of SIRT1 regulates apoptosis
Yamakuchi, M., Ferlito, M., & Lowenstein, C. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801613105 · Cited by 1,342
Post-translational modification of p53 in tumorigenesis
Bode, A. M., & Dong, Z. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1455 · Cited by 1,270
The multiple mechanisms that regulate p53 activity and cell fate
Hafner, A., Bulyk, M. L., Jambhekar, A., & Lahav, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0110-x · Cited by 1,129
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097
Post‐translational modifications and activation of p53 by genotoxic stresses
Appella, E., & Anderson, C. W. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02225.x · Cited by 1,079
HDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069
“This in turn modulates p53-mediated cell growth arrest and apoptosis [22,23].”
BackgroundDeubiquitination of p53 by HAUSP is an important pathway for p53 stabilization
Li, M., Chen, D., Shiloh, A., Luo, J., Nikolaev, A. Y., Qin, J., & Gu, W. (2002) · Nature · doi:10.1038/nature737 · Cited by 1,031
Self-citationThe role of histone deacetylases (HDACs) in human cancer
Ropero, S., & Esteller, M. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.01.001 · Cited by 997
ATP-dependent chromatin remodeling: genetics, genomics and mechanisms
Hargreaves, D. C., & Crabtree, G. R. (2011) · Cell Research · doi:10.1038/cr.2011.32 · Cited by 923
Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., & Gu, W. (2012) · Cell · doi:10.1016/j.cell.2012.04.026 · Cited by 912
Self-citationHuman SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence
Langley, E. (2002) · The EMBO Journal · doi:10.1093/emboj/21.10.2383 · Cited by 860
Acetylation Is Indispensable for p53 Activation
Tang, Y., Zhao, W., Chen, Y., Zhao, Y., & Gu, W. (2008) · Cell · doi:10.1016/j.cell.2008.03.025 · Cited by 838
Self-citationGao, L., Cueto, M. A., Asselbergs, F., & Atadja, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111871200 · Cited by 744
Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation
Brooks, C. L., & Gu, W. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00003-6 · Cited by 742
Self-citationTip60-Dependent Acetylation of p53 Modulates the Decision between Cell-Cycle Arrest and Apoptosis
Tang, Y., Luo, J., Zhang, W., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.021 · Cited by 727
Self-citationPirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation
Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J. M., Lozano, G., Hakem, R., & Benchimol, S. (2003) · Cell · doi:10.1016/s0092-8674(03)00193-4 · Cited by 722
Regulation and function of the p53 tumor suppressor protein
Ryan, K. M., Phillips, A. C., & Vousden, K. H. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00216-7 · Cited by 721
Barlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., & Berger, S. L. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00414-2 · Cited by 710
“We also expressed PID led to lowered p53 acetylation as well as identify a putative mechanism for the consequence of lowered transcription, apoptosis, and increased growth acetylation, which is the recruitment of coactivators/ (Luo et al., 2000).”
BackgroundHistone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code
THIAGALINGAM, S., CHENG, K., LEE, H. J., MINEVA, N., THIAGALINGAM, A., & PONTE, J. F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb05964.x · Cited by 700
Acetylation of non-histone proteins modulates cellular signalling at multiple levels
Spange, S., Wagner, T., Heinzel, T., & Krämer, O. H. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.08.027 · Cited by 664
The NAD metabolome — a key determinant of cancer cell biology
Chiarugi, A., Dölle, C., Felici, R., & Ziegler, M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3340 · Cited by 639
Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2
Hofmann, T. G., Möller, A., Sirma, H., Zentgraf, H., Taya, Y., Dröge, W., Will, H., & Schmitz, M. L. (2002) · Nature Cell Biology · doi:10.1038/ncb715 · Cited by 592
Yang, Z., Yan, C., Ma, J., Peng, P., Ren, X., Cai, S., Shen, X., Wu, Y., Zhang, S., Wang, X., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-022-00710-w · Cited by 589
MDM2–HDAC1-mediated deacetylation of p53 is required for its degradation
Ito, A., Kawaguchi, Y., Lai, C., Kovacs, J. J., Higashimoto, Y., Appella, E., & Yao, T. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf616 · Cited by 570
ARF-BP1/Mule Is a Critical Mediator of the ARF Tumor Suppressor
Chen, D., Kon, N., Li, M., Zhang, W., Qin, J., & Gu, W. (2005) · Cell · doi:10.1016/j.cell.2005.03.037 · Cited by 544
Self-citationAPPL Proteins Link Rab5 to Nuclear Signal Transduction via an Endosomal Compartment
Miaczynska, M., Christoforidis, S., Giner, A., Shevchenko, A., Uttenweiler-Joseph, S., Habermann, B., Wilm, M., Parton, R. G., & Zerial, M. (2004) · Cell · doi:10.1016/s0092-8674(04)00117-5 · Cited by 539
Cancer biology and NuRD: a multifaceted chromatin remodelling complex
Lai, A. Y., & Wade, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3091 · Cited by 539
p53 post-translational modification: deregulated in tumorigenesis
Dai, C., & Gu, W. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.09.002 · Cited by 523
Self-citationIndole: A privileged scaffold for the design of anti-cancer agents
Wan, Y., Li, Y., Yan, C., Yan, M., & Tang, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111691 · Cited by 516
Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer
Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., & Robson, C. N. (2004) · The Prostate · doi:10.1002/pros.20022 · Cited by 509
Acetylation of p53 inhibits its ubiquitination by Mdm2
Li, M., Luo, J., Brooks, C. L., & Gu, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200578200 · Cited by 503
Self-citationFei, P., & El-Deiry, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206677 · Cited by 498
Negative regulation of the deacetylase SIRT1 by DBC1
Zhao, W., Kruse, J.-P., Tang, Y., Jung, S. Y., Qin, J., & Gu, W. (2008) · Nature · doi:10.1038/nature06515 · Cited by 466
Self-citationModulation of p53 Function by SET8-Mediated Methylation at Lysine 382
Shi, X., Kachirskaia, I., Yamaguchi, H., West, L. E., Wen, H., Wang, E. W., Dutta, S., Appella, E., & Gozani, O. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.07.012 · Cited by 462
Espinosa, J. M., & Emerson, B. M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00283-0 · Cited by 439
SIRT Inhibitors Induce Cell Death and p53 Acetylation through Targeting Both SIRT1 and SIRT2
Peck, B., Chen, C.-Y., Ho, K.-K., Di Fruscia, P., Myatt, S. S., Coombes, R. C., Fuchter, M. J., Hsiao, C.-D., & Lam, E. W.-F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0971 · Cited by 433
Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo
Luo, J., Li, M., Tang, Y., Laszkowska, M., Roeder, R. G., & Gu, W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308762101 · Cited by 422
Self-citationEpigenetics in cancer stem cells
Toh, T. B., Lim, J. J., & Chow, E. K.-H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0596-9 · Cited by 422
miR-146a Suppresses Invasion of Pancreatic Cancer Cells
Li, Y., VandenBoom, T. G., Wang, Z., Kong, D., Ali, S., Philip, P. A., & Sarkar, F. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2792 · Cited by 421
Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse
Mishra, N., Reilly, C. M., Brown, D. R., Ruiz, P., & Gilkeson, G. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16153 · Cited by 408
p53 modifications: exquisite decorations of the powerful guardian
Liu, Y., Tavana, O., & Gu, W. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz060 · Cited by 392
Self-citationPolo, S. E., Kaidi, A., Baskcomb, L., Galanty, Y., & Jackson, S. P. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.188 · Cited by 374
“The work must be attributed back to the original author and commercial use is not permitted without specific permission.”
BackgroundInfluentialAcetylation inactivates the transcriptional repressor BCL6
Bereshchenko, O. R., Gu, W., & Dalla-Favera, R. (2002) · Nature Genetics · doi:10.1038/ng1018 · Cited by 394
Self-citationActive Regulator of SIRT1 Cooperates with SIRT1 and Facilitates Suppression of p53 Activity
Kim, E.-J., Kho, J.-H., Kang, M.-R., & Um, S.-J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.08.030 · Cited by 389
Control of Smad7 Stability by Competition between Acetylation and Ubiquitination
Grönroos, E., Hellman, U., Heldin, C.-H., & Ericsson, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00639-1 · Cited by 383
p53 and breast cancer, an update
Lacroix, M., Toillon, R.-A., & Leclercq, G. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01172 · Cited by 380
Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics
Ali, I., Conrad, R. J., Verdin, E., & Ott, M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00181 · Cited by 366
Tenenhaus, C., Subramaniam, K., Dunn, M. A., & Seydoux, G. (2001) · Genes & Development · doi:10.1101/gad.876201 · Cited by 357
Physical and Functional HAT/HDAC Interplay Regulates Protein Acetylation Balance
Peserico, A., & Simone, C. (2011) · BioMed Research International · doi:10.1155/2011/371832 · Cited by 357
Nikolaev, A. Y., Li, M., Puskas, N., Qin, J., & Gu, W. (2003) · Cell · doi:10.1016/s0092-8674(02)01255-2 · Cited by 356
Self-citationThe Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
Li, G., Tian, Y., & Zhu, W.-G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576946 · Cited by 352
Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases
Hu, E., Dul, E., Sung, C.-M., Chen, Z., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Liu, R., Lago, A., Hofmann, G., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055541 · Cited by 347
Identification of a small molecule inhibitor of Sir2p
Bedalov, A., Gatbonton, T., Irvine, W. P., Gottschling, D. E., & Simon, J. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261574398 · Cited by 346
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119504 · Cited by 345
Indole in the target-based design of anticancer agents: A versatile scaffold with diverse mechanisms
Dadashpour, S., & Emami, S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.065 · Cited by 343
SIRT1 and p53, effect on cancer, senescence and beyond
Yi, J., & Luo, J. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.05.002 · Cited by 340
Self-citationHistone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Wagner, J. M., Hackanson, B., Lübbert, M., & Jung, M. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0012-4 · Cited by 338
Activation of the p53 tumor suppressor protein
Vousden, K. H. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00035-5 · Cited by 337
Huang, B. H., Laban, M., Leung, C. H.-W., Lee, L., Lee, C. K., Salto-Tellez, M., Raju, G. C., & Hooi, S. C. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401567 · Cited by 337
Iron overloaded polarizes macrophage to proinflammation phenotype through ROS/acetyl‐p53 pathway
Zhou, Y., Que, K., Zhang, Z., Yi, Z. J., Zhao, P. X., You, Y., Gong, J., & Liu, Z. (2018) · Cancer Medicine · doi:10.1002/cam4.1670 · Cited by 336
Multiple roles of the tumor suppressor p53
Bargonetti, J., & Manfredi, J. J. (2002) · Current Opinion in Oncology · doi:10.1097/00001622-200201000-00015 · Cited by 332
p53 Acetylation: Regulation and Consequences
Reed, S., & Quelle, D. (2014) · Cancers · doi:10.3390/cancers7010030 · Cited by 332
SIRT1 Regulates HIV Transcription via Tat Deacetylation
Pagans, S., Pedal, A., North, B. J., Kaehlcke, K., Marshall, B. L., Dorr, A., Hetzer-Egger, C., Henklein, P., Frye, R., McBurney, M. W., et al. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030041 · Cited by 331
Structural Mechanism of the Bromodomain of the Coactivator CBP in p53 Transcriptional Activation
Mujtaba, S., He, Y., Zeng, L., Yan, S., Plotnikova, O., Sachchidanand, Sanchez, R., Zeleznik-Le, N. J., Ronai, Z., & Zhou, M.-M. (2004) · Molecular Cell · doi:10.1016/s1097-2765(03)00528-8 · Cited by 319
Lin, Z., Yang, H., Kong, Q., Li, J., Lee, S.-M., Gao, B., Dong, H., Wei, J., Song, J., Zhang, D. D., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.03.024 · Cited by 315
Activation and activities of the p53 tumour suppressor protein
Bálint, É., & Vousden, K. H. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2128 · Cited by 313
Gaughan, L., Logan, I. R., Cook, S., Neal, D. E., & Robson, C. N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203423200 · Cited by 310
Mitochondria, oxygen free radicals, and apoptosis
Raha, S., & Robinson, B. H. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1398 · Cited by 306
Histone Deacetylases and Mechanisms of Regulation of Gene Expression
Chen, H. P., Zhao, Y. T., & Zhao, T. C. (2015) · Critical Reviews in Oncogenesis · doi:10.1615/critrevoncog.2015012997 · Cited by 306
Nonhistone protein acetylation as cancer therapy targets
Singh, B. N., Zhang, G., Hwa, Y. L., Li, J., Dowdy, S. C., & Jiang, S.-W. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.62 · Cited by 300
Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression
Yamaguchi, T., Cubizolles, F., Zhang, Y., Reichert, N., Kohler, H., Seiser, C., & Matthias, P. (2010) · Genes & Development · doi:10.1101/gad.552310 · Cited by 291
PIAS/SUMO: new partners in transcriptional regulation
Schmidt, D., & M�ller, S. (2003) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3129-1 · Cited by 284
Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Bose, P., Dai, Y., & Grant, S. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.04.004 · Cited by 280
The impact of acetylation and deacetylation on the p53 pathway
Brooks, C. L., & Gu, W. (2011) · Protein & Cell · doi:10.1007/s13238-011-1063-9 · Cited by 280
Self-citationZhao, Y., Lu, S., Wu, L., Chai, G., Wang, H., Chen, Y., Sun, J., Yu, Y., Zhou, W., Zheng, Q., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2782-2790.2006 · Cited by 277
Class II histone deacetylases: Structure, function, and regulation
Bertos, N. R., Wang, A. H., & Yang, X.-J. (2001) · Biochemistry and Cell Biology · doi:10.1139/bcb-79-3-243 · Cited by 276
Wang, R., Cherukuri, P., & Luo, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413930200 · Cited by 275
Self-citationLiver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks
Knutson, S. K., Chyla, B. J., Amann, J. M., Bhaskara, S., Huppert, S. S., & Hiebert, S. W. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.51 · Cited by 271
“Although HDACs have many non-histone protein targets for deacetylation (Juan et al, 2000; Luo et al, 2000; Ashburner et al, 2001; Hubbert et al, 2002; Shimazu et al, 2006; Gregoire et al, 2007), the disruption of liver metabolism was evident at the level of transcription and was accompa- nied by…”
BackgroundButyrate Suppression of Colonocyte NF-κB Activation and Cellular Proteasome Activity
Yin, L., Laevsky, G., & Giardina, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105170200 · Cited by 266
MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation
Wang, C., Ivanov, A., Chen, L., Fredericks, W. J., Seto, E., Rauscher, F. J., & Chen, J. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600791 · Cited by 263
Monte, M., Simonatto, M., Peche, L. Y., Bublik, D. R., Gobessi, S., Pierotti, M. A., Rodolfo, M., & Schneider, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510834103 · Cited by 257
Faraco, G., Pancani, T., Formentini, L., Mascagni, P., Fossati, G., Leoni, F., Moroni, F., & Chiarugi, A. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.027912 · Cited by 255
FOG‐1 recruits the NuRD repressor complex to mediate transcriptional repression by GATA‐1
Hong, W., Nakazawa, M., Chen, Y., Kori, R., Vakoc, C. R., Rakowski, C., & Blobel, G. A. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600703 · Cited by 253
The NuRD chromatin–remodeling complex regulates signaling and repair of DNA damage
Smeenk, G., Wiegant, W. W., Vrolijk, H., Solari, A. P., Pastink, A., & van Attikum, H. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201001048 · Cited by 243
SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities
David, G., Neptune, M. A., & DePinho, R. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203690200 · Cited by 236
Jin, Y.-H., Jeon, E.-J., Li, Q.-L., Lee, Y. H., Choi, J.-K., Kim, W.-J., Lee, K.-Y., & Bae, S.-C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313120200 · Cited by 211
Histone Deacetylase 3 Interacts with and Deacetylates Myocyte Enhancer Factor 2
Grégoire, S., Xiao, L., Nie, J., Zhang, X., Xu, M., Li, J., Wong, J., Seto, E., & Yang, X.-J. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00882-06 · Cited by 203
Krummel, K. A., Lee, C. J., Toledo, F., & Wahl, G. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503068102 · Cited by 187
Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
Yan, W., Liu, S., Xu, E., Zhang, J., Zhang, Y., Chen, X., & Chen, X. (2013) · Oncogene · doi:10.1038/onc.2012.81 · Cited by 153
Metadata
- Authors
- Luo, J., Su, F., Chen, D., Shiloh, A., & Gu, W.
- Venue
- Nature
- Published
- 2000-11-16
- Volume
- 408
- Issue
- 6810
- Pages
- 377-381
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1493846190
- Cited by
- 818
- References
- 30
- FWCI
- 12.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.